Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Possibilities of using amantadines in the setting of the novel coronavirus infection in patients with Parkinson's disease

https://doi.org/10.14412/2074-2711-2021-6-67-72

Full Text:

Abstract

The novel coronavirus infection pandemic prompted not only the development of vaccines, but also the study of the effectiveness of already known drugs with antiviral activity. These drugs include adamantanes.
Objective: to assess possible mechanisms of antiviral action of amantadine and memantine.
Patients and methods. The study included 75 patients with Parkinson's disease (PD): 49 (65.3%) women and 26 (34.7%) men. The age of the patients ranged from 37 to 88 years (mean age: 65±7 years). The duration of the disease varied from 1 to 25 years (mean 12±7 years). Among the monitored PD patients, 22 (29.3%) had a novel coronavirus infection. Of 22 patients with coronavirus infection, 8 (36.4%) patients received adamantanes (four – amantadine sulfate, three – amantadine hydrochloride, one – memantine) in the complex therapy of PD for at least 3 months. On average, the duration of adamantane administration was 8±5 months.
Results and discussion. PD patients who received adamantanes were less likely to develop COVID-19 than those who did not take adamantanes (p<0.05). At the same time, there were no significant differences in gender, age, duration of the disease and concomitant pathology in the com pared groups (p>0.05). Among patients who received adamantanes, the disease proceeded more easily, the number of cases of pneumonia was 3 times less (odds ratio 3; 95% confidence interval 0.44–20.3). In this group, no lethal outcomes were recorded, however, due to the small sample of patients, the differences between the groups were not statistically significant (÷2=1.99; p>0.05).
Conclusion. The results of a retrospective study showed that the use of amantadine and memantine in patients with PD may have an effect on reducing morbidity and mortality in the novel coronavirus infection. This is consistent with published clinical observations suggesting a possible protective effect of amantadine and memantine against coronavirus infection.

About the Authors

E. A. Katunina
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neurodegenerative Diseases, Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation

1, Ostrovityanov St., Moscow 117997, Russia

1, Ostrovityanov St., Build 10, Moscow 117513, Russia



Yu. N. Bezdolnyi
City Outpatient Clinic №107, Moscow Healthcare Department
Russian Federation

 24, Dekabristov St., Moscow 127273, Russia 



N. N. Shipilova
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neurodegenerative Diseases, Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation

1, Ostrovityanov St., Moscow 117997, Russia

1, Ostrovityanov St., Build 10, Moscow 117513, Russia



References

1. Katunina EA. Amantadines in the treatment of Parkinson's disease. New opportunities in the conditions of COVID-19. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):101-6. doi: 10.17116/jnevro2021121041101 (In Russ.).

2. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016 May;129:21-38. doi: 10.1016/j.antiviral.2016.01.012. Epub 2016 Feb 9.

3. Kolocouris A. Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A. J Med Chem. 2014 Jun 12;57(11):4629-39. doi: 10.1021/jm500598u. Epub 2014 May 15.

4. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza a virus M2 protein: characterization of the amantadine block. J Virol. 1993 Sep;67(9):5585-94. doi: 10.1128/JVI.67.9.5585-5594.1993

5. Thomaston JL, Polizzi NF, Konstantinidi A, et al. Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of HydrogenBonded Waters. J Am Chem Soc. 2018 Nov 14;140(45):15219-26. doi: 10.1021/jacs.8b06741. Epub 2018 Sep 12.

6. Shtok VN, Fedorova NV. Parkinson's disease. In: Shtok VN, Ivanova-Smolenskaya IA, Levin OS. Ekstrapiramidnye rasstroystva: rukovodstvo po lecheniyu [Extrapyramidal Disorders: A Guide to Diagnosis and Treatment]. Moscow: MEDpress-inform; 2002 (In Russ.).

7. Aranda-Abreu GE, Aguilar ME, Covarrubias DH, Duran FR. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020 Jul;140:109755. doi: 10.1016/j.mehy.2020.109755. Epub 2020 Apr 25.

8. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020 Jun;55(6):106004. doi: 10.1016/j.ijantimicag.2020.106004. Epub 2020 Apr 30.

9. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):134. doi: 10.1038/s41392-021-00558-8

10. Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y

11. Zhou Y, Gammeltoft KA, Galli A, et al. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. Viruses. 2021 Oct 15;13(10):2082. doi: 10.3390/v13102082

12. Araujo R, Aranda-Martinez JD, Aranda-Abreu GE. Amantadine Treatment for People with COVID-19. Arch Med Res. 2020 Oct;51(7):739-40. doi: 10.1016/j.arcmed.2020.06.009. Epub 2020 Jun 12.

13. Cortes-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021 Jun;73(3):962-5. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18.

14. Brison E, Jacomy H, Desforges M, Talbot PJ. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol. 2014 Feb;88(3):1548-63. doi: 10.1128/JVI.02972-13. Epub 2013 Nov 13.

15. Wu HM, Tzeng NS, Qian L, et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 2009 Sep;34(10):2344-57. doi: 10.1038/npp.2009.64. Epub 2009 Jun 17.

16. Honegger UE, Quack G, Wiesmann UN. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol Toxicol. 1993 Oct;73(4):202-8. doi: 10.1111/j.1600-0773.1993.tb01564.x

17. Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a Mediator of ACE-2. Eur Respir J. 2020 Jun 4;55(6):2001261. doi: 10.1183/13993003.01261-2020. Print 2020 Jun.

18. Hasanagic S, Serdarevic F. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond. Eur Respir J. 2020 Aug 13;56(2):2001610. doi: 10.1183/13993003.01610-2020. Print 2020 Aug.

19. Farsalinos K, Angelopoulou A, Alexandris N, Poulas K.COVID-19 and the nicotinic cholinergic system. Eur Respir J. 2020 Jul 16;56(1):2001589. doi: 10.1183/13993003.01589-2020. Print 2020 Jul.

20. Li YC, Bai WZ, Hashikawa T. Response to commentary on «The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients». J Med Virol. 2020 Jul;92(7):707-9. doi: 10.1002/jmv.25824. Epub 2020 Apr 10.

21. Baig AM.Computing the Effects of SARS-CoV-2 on Respiration Regulatory Mechanisms in COVID-19. ACS Chem Neurosci. 2020 Aug 19;11(16):2416-21. doi: 10.1021/acschemneuro.0c00349. Epub 2020 Aug 11.

22. Murta V, Villarreal A, Ramos AJ. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders? ASN Neuro. Jan-Dec 2020;12:1759091420954960. doi: 10.1177/1759091420954960

23. Brenner SR, Butterworth RF. Repurposing of adamantanes with transmitter receptor antagonist properties for the prevention/treatment of COVID-19. J Pharmaceu Pharmacol. 2020;8(1):4. doi: 10.13188/2327-204X.S200005

24. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JAG. Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? J Pers Med. 2020 Nov 9;10(4):217. doi: 10.3390/jpm10040217

25. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671

26. Jeppesen MG, Toft-Bertelsen TL, Kledal TN, Rosenkilde MM. Amantadin has potential for the treatment of COVID-19 because it targets known and novel ion channels encoded by SARS-CoV-2. Res Sq. 2021. doi: 10.21203/rs.3.rs-121743/v1

27. Grieb P, Rejdak K. Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19? Folia Neuropathol. 2021;59(2):113-20. doi: 10.5114/fn.2021.107572

28. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 Jul;42:102163. doi: 10.1016/j.msard.2020.102163. Epub 2020 Apr 30.

29. Aranda-Abreu GE, Aranda-Martinez JD, Araujo R, et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep. 2020 Dec;72(6):1538-41. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.

30. Bodnar W, Aranda-Abreu G, Slabon-Willand M, et al. The efficacy of amantadine hydrochloride in the treatment of COVID-19 – a single-center observation study. Res Square. 2021. doi: 10.21203/rs.3.rs-493154/v1


For citation:


Katunina E.A., Bezdolnyi Yu.N., Shipilova N.N. Possibilities of using amantadines in the setting of the novel coronavirus infection in patients with Parkinson's disease. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):67-72. (In Russ.) https://doi.org/10.14412/2074-2711-2021-6-67-72

Views: 168


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)